FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W35516085> ?p ?o ?g. }

• W35516085 endingPage "34" @default.
• W35516085 startingPage "1228" @default.
• W35516085 abstract "To evaluate the efficacy and safety of leflunomide in comparison with methotrexate (MTX) on patients with rheumatoid arthritis (RA) in China.Five hundred and sixty-six patients with active rheumatoid arthritis were randomly assigned to receive leflunomide at 20 mg once daily or MTX at 15 mg once weekly in a controlled trial. Five hundred and four patients completed the 12-week treatment and some patients continued the treatment for 24 weeks.Both leflunomide and MTX could improve the symptoms, signs, and joint function, but there were no changes in X-ray observations of patients with rheumatoid arthritis. In the leflunomide group, the overall rates of effectiveness at 12 weeks and 24 weeks were 86.94% and 92.31% respectively; the rates of remarkable improvement were 64.95% and 79.81% respectively. In the MTX group, the overall rates of effectiveness at 12 weeks and 24 weeks were 84.04% and 83.15% respectively; the rates of remarkable improvement were 56.81% and 75.28% respectively. According to intent-to-treat analysis, the ACR 20% response rates at 12 weeks and 24 weeks in the leflunomide group were 62.54% and 67.18% respectively, compared with 60.08% and 61.32% respectively in MTX group. No statistical differences were shown in the efficacy between the two groups (P > 0.05). The adverse events in the leflunomide group were gastrointestinal symptoms, skin rash, alopecia, nervous system symptoms, decreased leukocyte count, and elevation of alanine aminotransferase (ALT). Most of these side effects were mild and transient. The incidence of adverse events in the leflunomide group was 16.84%, significantly lower than that in MTX group (28.17%, P = 0.002).Leflunomide is effective in the treatment of RA with less adverse events than MTX. Its efficacy is similar to MTX, but the incidence of adverse events and the rate of withdrawal due to adverse events were lower in the leflunomide group than in MTX group." @default.
• W35516085 created "2016-06-24" @default.
• W35516085 creator A5001062703 @default.
• W35516085 creator A5003518511 @default.
• W35516085 creator A5008625013 @default.
• W35516085 creator A5008660322 @default.
• W35516085 creator A5009189155 @default.
• W35516085 creator A5021295149 @default.
• W35516085 creator A5026024427 @default.
• W35516085 creator A5029946717 @default.
• W35516085 creator A5034417510 @default.
• W35516085 creator A5044524874 @default.
• W35516085 creator A5047873063 @default.
• W35516085 creator A5056033075 @default.
• W35516085 creator A5058722902 @default.
• W35516085 creator A5073625428 @default.
• W35516085 date "2003-08-01" @default.
• W35516085 modified "2023-09-26" @default.
• W35516085 title "Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial." @default.
• W35516085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12935395" @default.
• W35516085 hasPublicationYear "2003" @default.
• W35516085 type Work @default.
• W35516085 sameAs 35516085 @default.
• W35516085 citedByCount "12" @default.
• W35516085 countsByYear W355160852012 @default.
• W35516085 countsByYear W355160852018 @default.
• W35516085 countsByYear W355160852020 @default.
• W35516085 countsByYear W355160852022 @default.
• W35516085 crossrefType "journal-article" @default.
• W35516085 hasAuthorship W35516085A5001062703 @default.
• W35516085 hasAuthorship W35516085A5003518511 @default.
• W35516085 hasAuthorship W35516085A5008625013 @default.
• W35516085 hasAuthorship W35516085A5008660322 @default.
• W35516085 hasAuthorship W35516085A5009189155 @default.
• W35516085 hasAuthorship W35516085A5021295149 @default.
• W35516085 hasAuthorship W35516085A5026024427 @default.
• W35516085 hasAuthorship W35516085A5029946717 @default.
• W35516085 hasAuthorship W35516085A5034417510 @default.
• W35516085 hasAuthorship W35516085A5044524874 @default.
• W35516085 hasAuthorship W35516085A5047873063 @default.
• W35516085 hasAuthorship W35516085A5056033075 @default.
• W35516085 hasAuthorship W35516085A5058722902 @default.
• W35516085 hasAuthorship W35516085A5073625428 @default.
• W35516085 hasConcept C126322002 @default.
• W35516085 hasConcept C197934379 @default.
• W35516085 hasConcept C2775905006 @default.
• W35516085 hasConcept C2777077863 @default.
• W35516085 hasConcept C2777575956 @default.
• W35516085 hasConcept C2778570526 @default.
• W35516085 hasConcept C2781059491 @default.
• W35516085 hasConcept C71924100 @default.
• W35516085 hasConcept C90924648 @default.
• W35516085 hasConceptScore W35516085C126322002 @default.
• W35516085 hasConceptScore W35516085C197934379 @default.
• W35516085 hasConceptScore W35516085C2775905006 @default.
• W35516085 hasConceptScore W35516085C2777077863 @default.
• W35516085 hasConceptScore W35516085C2777575956 @default.
• W35516085 hasConceptScore W35516085C2778570526 @default.
• W35516085 hasConceptScore W35516085C2781059491 @default.
• W35516085 hasConceptScore W35516085C71924100 @default.
• W35516085 hasConceptScore W35516085C90924648 @default.
• W35516085 hasIssue "8" @default.
• W35516085 hasLocation W355160851 @default.
• W35516085 hasOpenAccess W35516085 @default.
• W35516085 hasPrimaryLocation W355160851 @default.
• W35516085 hasRelatedWork W1020987747 @default.
• W35516085 hasRelatedWork W2102691073 @default.
• W35516085 hasRelatedWork W2353652814 @default.
• W35516085 hasRelatedWork W2368117966 @default.
• W35516085 hasRelatedWork W2372955595 @default.
• W35516085 hasRelatedWork W2373525365 @default.
• W35516085 hasRelatedWork W2377510725 @default.
• W35516085 hasRelatedWork W2385808951 @default.
• W35516085 hasRelatedWork W3017376994 @default.
• W35516085 hasRelatedWork W3029512793 @default.
• W35516085 hasVolume "116" @default.
• W35516085 isParatext "false" @default.
• W35516085 isRetracted "false" @default.
• W35516085 magId "35516085" @default.
• W35516085 workType "article" @default.